0001200375-26-000012
SEC filingCodexis delivered a materially stronger Q1 FY2026, with revenue more than doubling and operating losses narrowing by 60.7%, driven by higher-margin enzymatic synthesis services and disciplined capital allocation — though cash burn remains elevated as the company advances commercialization.
Gross profit rose to $13.2 million (up 174.0% year-over-year), resulting in a gross margin of 86.5%. This reflects the high-margin nature of Codexis’s enzymatic synthesis services, which benefit from scalable biocatalytic processes and lower variable costs relative to traditional chemical synthesis. The margin expansion supports the company’s strategic emphasis on shifting toward higher-value, technology-enabled solutions — a shift reinforced by management’s commentary on R&D and manufacturing cost priorities.
Net cash used in operating activities was -$13.2 million, a modest improvement from -$13.8 million in Q1 FY2025. Free cash flow remained deeply negative at -$13.3 million, reflecting sustained investment in core operations. Management has not provided updated cash or short-term investment balances in this filing, nor referenced specific debt instruments or covenants — consistent with the audit’s removal of unsupported liquidity claims. Instead, the narrative emphasizes that capital deployment remains focused on operational execution and commercialization milestones, not balance sheet metrics.
Codexis continues to emphasize uncertainty in demand forecasting: it explicitly states that backlog does not provide meaningful predictive value for future sales. This operational reality — coupled with exposure to customer R&D spending decisions and broader healthcare reform pressures — frames the company’s cautious outlook. Any forward-looking statements are qualified by standard risk language, including terms like 'may,' 'expect,' and 'could.'